Qixiang Geng, Zixuan Jiang, Woong Sub Byun, Katherine A. Donovan, Zhe Zhuang, Fen Jiang, Hannah M. Jones, Hlib Razumkov, Michelle T. Tang, Roman C. Sarott, Eric S. Fischer, Steven M. Corsello, Stephen M. Hinshaw, Nathanael S. Gray
{"title":"Development of Potent and Selective CK1α Molecular Glue Degraders","authors":"Qixiang Geng, Zixuan Jiang, Woong Sub Byun, Katherine A. Donovan, Zhe Zhuang, Fen Jiang, Hannah M. Jones, Hlib Razumkov, Michelle T. Tang, Roman C. Sarott, Eric S. Fischer, Steven M. Corsello, Stephen M. Hinshaw, Nathanael S. Gray","doi":"10.1021/acs.jmedchem.4c02415","DOIUrl":null,"url":null,"abstract":"Molecular glue degraders (MGDs) are small molecules that facilitate proximity between a target protein and an E3 ubiquitin ligase, thereby inducing target protein degradation. Glutarimide-containing compounds are MGDs that bind cereblon (CRBN) and recruit neosubstrates. Through explorative synthesis of a glutarimide-based library, we discovered a series of molecules that induce casein kinase 1 alpha (CK1α) degradation. By scaffold hopping and rational modification of the chemical scaffold, we identified an imidazo[1,2-<i>a</i>]pyrimidine compound that induces potent and selective CK1α degradation. A structure–activity relationship study of the lead compound, <b>QXG-6442</b>, identified the chemical features that contribute to degradation potency and selectivity compared to other frequently observed neosubstrates. The glutarimide library screening and structure–activity relationship medicinal chemistry approach we employed is generally useful for developing new molecular glue degraders toward new targets of interest.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"12 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02415","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Molecular glue degraders (MGDs) are small molecules that facilitate proximity between a target protein and an E3 ubiquitin ligase, thereby inducing target protein degradation. Glutarimide-containing compounds are MGDs that bind cereblon (CRBN) and recruit neosubstrates. Through explorative synthesis of a glutarimide-based library, we discovered a series of molecules that induce casein kinase 1 alpha (CK1α) degradation. By scaffold hopping and rational modification of the chemical scaffold, we identified an imidazo[1,2-a]pyrimidine compound that induces potent and selective CK1α degradation. A structure–activity relationship study of the lead compound, QXG-6442, identified the chemical features that contribute to degradation potency and selectivity compared to other frequently observed neosubstrates. The glutarimide library screening and structure–activity relationship medicinal chemistry approach we employed is generally useful for developing new molecular glue degraders toward new targets of interest.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.